Neuburgh Advisers’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Neuburgh Advisers’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,456	Closed	-$8K	–	928
2018 Q4	$8K	Sell	3,456 -10,096	-74%	-$89K	﹤0.01%	887
2018 Q3	$201K	Buy	13,552 +656	+5%	+$10.4K	0.01%	698
2018 Q2	$196K	Buy	12,896 +5,552	+76%	+$94.2K	0.01%	653
2018 Q1	$138K	Buy	+7,344	New	+$128K	﹤0.01%	729

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuburgh Advisers's SNNA Position: Q1 2019 in Review

Neuburgh Advisers sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 3,456 shares — an estimated $8K sold.

Neuburgh Advisers first reported a position in SNNA in Q1 2018 and held it in 4 quarters. The position peaked at $201K in Q3 2018. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

Neuburgh Advisers reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Neuburgh Advisers sold 3,456 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $8K.
Neuburgh Advisers first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Neuburgh Advisers's Sienna Biopharmaceuticals, Inc. position peaked at $201K in Q3 2018.
57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on Neuburgh Advisers's 13F filing for Q1 2019, filed 13 May 2019.